Nektar scores $175M pact for pneumonia therapy

Nektar Therapeutics is getting $50 million up front in a $175 million licensing deal with Bayer Healthcare for the successful development of a new therapy for severe pneumonia. Nektar will deploy its pulmonary technology to deliver aminoglycoside antibiotic NKTR-061. The pact includes a rich co-promotion deal for the U.S. market along with a royalty split on sales outside the U.S.

- see this release
- read the AFX report on the deal

Related Articles:
Nektar settles university patent fight. Report
Nektar gains fast track for lung infection drug. Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.